

CA 180188 Trial

Official Title: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects who are Experiencing Clinical Benefit on Current START Protocols: Long Term Safety and Efficacy

Primary Outcomes: To determine the long term safety and tolerability of treatment with dasatinib

Secondary Outcomes: To collect long term efficacy of treatment with dasatinib in terms of molecular response

Ages Eligible for Study: 18 years to Any Age

Genders Eligible for Study: Male and Female

Health of Volunteers: People with the conditions listed in this trial can participate as controls.

Key Inclusion Criteria:

- 1) Signed Written Informed Consent
- 2) Target Population (consistent with prior START protocols)
 - a) Treatment on protocols CA180005, CA180006, CA180013, CA180015 or CA180017
 - b) Receiving clinical benefit with dasatinib or imatinib (study CA180017) in the opinion of the Investigator.
- 3) Age and Sex Men and women, ages 18 and older may participate. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month (4 weeks) before and at least 3 months (12 weeks) after the last dose of investigational product in such a manner that risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \geq 12 consecutive months; or women on hormone replacement therapy [HRT] with documented serum follicle stimulating hormone [FSH] level $>$ 35 mIU/mL). Even women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product.

Key Exclusion Criteria:

- 1) Sex and Reproductive Status
 - a) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least one month (4 weeks) before and for at least 3 months (12 weeks) after the last dose of study medication.
 - b) WOCBP using a prohibited contraceptive method (Not applicable for this study)
 - c) Women who are pregnant or breastfeeding
 - d) Women with a positive pregnancy test on enrollment or prior to investigational product administration.
 - e) Sexually active fertile men whose sexual partner(s) are WOCBP, who are unwilling or unable to use an effective method to avoid pregnancy for the entire study period and for at least 3 months (12 weeks) after completion of study medication
- 2) Medical History and Concurrent Diseases
 - a) A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
 - b) Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
- 3) Prohibited Treatments and/or Therapies
 - a) Subjects currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes

CA 180188 Trial

including, but not limited to:

- quinidine, procainamide, disopyramide
- amiodarone, sotalol, ibutilide, dofetilide
- erythromycins, clarithromycin
- chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, ziprasidone
- cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine

See Appendix 2 for a more complete list.

b) Subjects taking medications known to be potent CYP3A4 inhibitors (i.e. ketoconazole, ritonavir) or inducers (i.e., rifampin, efavirenz).

4) Other Exclusion Criteria

- a) Prisoners or subjects who are involuntarily incarcerated
- b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness

Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and to ensure that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.